MLL
PRQR icon

Moody Lynn & Lieberson’s ProQR Therapeutics PRQR Stock Holding History

Moody Lynn & Lieberson’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.5K Hold
25,000
– – ﹤0.01% 249
2025
Q4 		$50.5K Buy
+25,000
New +$58.4K ﹤0.01% 264

Other funds holding PRQR

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Moody Lynn & Lieberson's PRQR Position: Q1 2026 in Review

Moody Lynn & Lieberson held its ProQR Therapeutics (PRQR) position steady in Q1 2026 at 25,000 shares worth $40.5K. The position accounts for ﹤0.01% of the portfolio, ranked #249.

Moody Lynn & Lieberson first reported a position in PRQR in Q4 2025 and has held it in 2 quarters since. The position peaked at $50.5K in Q4 2025. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

  • Moody Lynn & Lieberson held 25,000 shares of ProQR Therapeutics worth $40.5K as of Q1 2026.
  • Moody Lynn & Lieberson left its ProQR Therapeutics share count unchanged in Q1 2026.
  • ProQR Therapeutics made up ﹤0.01% of Moody Lynn & Lieberson's portfolio in Q1 2026, its #249 holding.
  • Moody Lynn & Lieberson first reported a position in ProQR Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Moody Lynn & Lieberson's ProQR Therapeutics position peaked at $50.5K in Q4 2025.
  • 69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Moody Lynn & Lieberson's 13F filing for Q1 2026, filed 13 Apr 2026.